

**Press Release**  
**New Delhi**  
**July 9, 2008**

**For Immediate Release**

**Panacea Biotec receives US Patent for 'Thank God'™**

Panacea Biotec, India's leading research based Health Management Company involved in research, manufacturing and marketing of branded pharmaceutical formulations, vaccines and natural products has been granted a patent from US Patent & Trademark Office for their product **Thank God™** (Euphorbia Prostrata) for effective management of hemorrhoids & piles (Patent No. 7,371,412 B2). With this, the company is looking forward to launch this product in high potential markets of US and EU. As per current industry trends, the total potential of anti-hemorrhoids & piles market in US & EU is between USD 500-600 million.

**Highlighting this achievement, Mr. Rajesh Jain, JMD Panacea Biotec said, "It is certain that innovative products would achieve a stronghold worldwide, as compared to conventional products. Thank God™ (Euphorbia Prostrata) is an innovative, comprehensive solution for management of hemorrhoids & piles. The product is doing extremely well in the domestic market. This US patent for Thank God™ would offer us an excellent opportunity to enter the US and EU markets, which is an important part of our global strategy."**

**About Panacea Biotec**

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2<sup>nd</sup> largest vaccine producer in India. Panacea Biotec has been ranked as the 3<sup>rd</sup> largest biotechnology company (ABLE Survey 2007) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has four research and development centers. It has around 2800 employees including over 280 highly skilled scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

**For further details please contact:**

Mr. Pradeep Kumar Jain  
GM - Corporate Communications & Govt. Affairs  
Mobile: 09313482886  
Land Line: 011-41678000; Fax: 011-41679096  
Email: [pradeepjain@panaceabiotec.com](mailto:pradeepjain@panaceabiotec.com) ,  
Website: [www.panaceabiotec.com](http://www.panaceabiotec.com)

™ Trade Mark in India

**Disclaimer**

Except for the historical information contained herein, statements in this Release which contain words or phrases such as 'will', 'would', 'indicating', 'expected to' etc., and similar expressions or variations of such expressions may constitute 'forward-looking statements'. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, future business plans, our growth and expansion in business, the impact of any acquisitions, our financial capabilities, technological implementation and changes, the actual growth in demand for our products and services, cash flow projections, our exposure to market risks as well as other general risks applicable to the business or industry. Panacea Biotec undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date thereof.